#cd47 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #cd47, aggregated by home.social.
-
Magrolimab is an anti-CD47
'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related expanded access programs, on full clinical hold'
#Leukemia #ClinicalTrial #CD47 #Hematology -
Magrolimab is an anti-CD47
'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related expanded access programs, on full clinical hold'
#Leukemia #ClinicalTrial #CD47 #Hematology -
Magrolimab is an anti-CD47
'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related expanded access programs, on full clinical hold'
#Leukemia #ClinicalTrial #CD47 #Hematology -
Magrolimab is an anti-CD47
'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related expanded access programs, on full clinical hold'
#Leukemia #ClinicalTrial #CD47 #Hematology -
" Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies
targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combination with myeloid
#ImmuneCheckpointBlockade (#CD47/SIRPa, or VISTA) could be a feasible strategy to explore in future studies"Krijgsman et al. from Vercoulen lab in the #UMCUtrecht, on #bioRXiv:
https://www.biorxiv.org/content/10.1101/2023.06.28.546852v1 -
" Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies
targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combination with myeloid
#ImmuneCheckpointBlockade (#CD47/SIRPa, or VISTA) could be a feasible strategy to explore in future studies"Krijgsman et al. from Vercoulen lab in the #UMCUtrecht, on #bioRXiv:
https://www.biorxiv.org/content/10.1101/2023.06.28.546852v1 -
" Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies
targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combination with myeloid
#ImmuneCheckpointBlockade (#CD47/SIRPa, or VISTA) could be a feasible strategy to explore in future studies"Krijgsman et al. from Vercoulen lab in the #UMCUtrecht, on #bioRXiv:
https://www.biorxiv.org/content/10.1101/2023.06.28.546852v1 -
" Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies
targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combination with myeloid
#ImmuneCheckpointBlockade (#CD47/SIRPa, or VISTA) could be a feasible strategy to explore in future studies"Krijgsman et al. from Vercoulen lab in the #UMCUtrecht, on #bioRXiv:
https://www.biorxiv.org/content/10.1101/2023.06.28.546852v1